Limits...
Metabonomics study of the therapeutic mechanism of Gynostemma pentaphyllum and atorvastatin for hyperlipidemia in rats.

Wang M, Wang F, Wang Y, Ma X, Zhao M, Zhao C - PLoS ONE (2013)

Bottom Line: Using (1)H-NMR-based metabonomics, we elucidated the therapeutic mechanisms of GP and atorvastatin.Orthogonal Partial Least Squares-Discriminant analysis (OPLS-DA) plotting of the metabolic state and analysis of potential biomarkers in the plasma and liver correlated well with the results of biochemical assays.GP can effectively affect lipid metabolism, and it exerts its anti-hyperlipidemia effect by elevating the level of phosphatidylcholine and decreasing the level of trimethylamine N-oxide (TMAO).

View Article: PubMed Central - PubMed

Affiliation: School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China ; School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.

ABSTRACT
Gynostemma pentaphyllum (GP) is widely used for the treatment of diseases such as hyperlipidemia, fatty liver and obesity in China, and atorvastatin is broadly used as an anti-hyperlipidemia drug. This research focuses on the plasma and liver metabolites in the following four groups of rats: control, a hyperlipidemia model, a hyperlipidemia model treated with GP and a hyperlipidemia model treated with atorvastatin. Using (1)H-NMR-based metabonomics, we elucidated the therapeutic mechanisms of GP and atorvastatin. Orthogonal Partial Least Squares-Discriminant analysis (OPLS-DA) plotting of the metabolic state and analysis of potential biomarkers in the plasma and liver correlated well with the results of biochemical assays. GP can effectively affect lipid metabolism, and it exerts its anti-hyperlipidemia effect by elevating the level of phosphatidylcholine and decreasing the level of trimethylamine N-oxide (TMAO). In contrast, atorvastatin affects hyperlipidemia mainly during lipid metabolism and protein metabolism in vivo.

Show MeSH

Related in: MedlinePlus

Summary of the metabolic pathways related to the metabolites that changed significantly in the hyperlipidemia model.“↑” and “↓” indicate that the compound is up- and down-regulated compared with the control group.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3815346&req=5

pone-0078731-g005: Summary of the metabolic pathways related to the metabolites that changed significantly in the hyperlipidemia model.“↑” and “↓” indicate that the compound is up- and down-regulated compared with the control group.

Mentions: The discovery of biomarkers and the biological explanations mentioned above can be used to analyze the pathogenesis of hyperlipidemia through metabolic pathways, and these results can likewise play an important role in assisting the clinical diagnose of hyperlipidemia (Figure 5).


Metabonomics study of the therapeutic mechanism of Gynostemma pentaphyllum and atorvastatin for hyperlipidemia in rats.

Wang M, Wang F, Wang Y, Ma X, Zhao M, Zhao C - PLoS ONE (2013)

Summary of the metabolic pathways related to the metabolites that changed significantly in the hyperlipidemia model.“↑” and “↓” indicate that the compound is up- and down-regulated compared with the control group.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3815346&req=5

pone-0078731-g005: Summary of the metabolic pathways related to the metabolites that changed significantly in the hyperlipidemia model.“↑” and “↓” indicate that the compound is up- and down-regulated compared with the control group.
Mentions: The discovery of biomarkers and the biological explanations mentioned above can be used to analyze the pathogenesis of hyperlipidemia through metabolic pathways, and these results can likewise play an important role in assisting the clinical diagnose of hyperlipidemia (Figure 5).

Bottom Line: Using (1)H-NMR-based metabonomics, we elucidated the therapeutic mechanisms of GP and atorvastatin.Orthogonal Partial Least Squares-Discriminant analysis (OPLS-DA) plotting of the metabolic state and analysis of potential biomarkers in the plasma and liver correlated well with the results of biochemical assays.GP can effectively affect lipid metabolism, and it exerts its anti-hyperlipidemia effect by elevating the level of phosphatidylcholine and decreasing the level of trimethylamine N-oxide (TMAO).

View Article: PubMed Central - PubMed

Affiliation: School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China ; School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.

ABSTRACT
Gynostemma pentaphyllum (GP) is widely used for the treatment of diseases such as hyperlipidemia, fatty liver and obesity in China, and atorvastatin is broadly used as an anti-hyperlipidemia drug. This research focuses on the plasma and liver metabolites in the following four groups of rats: control, a hyperlipidemia model, a hyperlipidemia model treated with GP and a hyperlipidemia model treated with atorvastatin. Using (1)H-NMR-based metabonomics, we elucidated the therapeutic mechanisms of GP and atorvastatin. Orthogonal Partial Least Squares-Discriminant analysis (OPLS-DA) plotting of the metabolic state and analysis of potential biomarkers in the plasma and liver correlated well with the results of biochemical assays. GP can effectively affect lipid metabolism, and it exerts its anti-hyperlipidemia effect by elevating the level of phosphatidylcholine and decreasing the level of trimethylamine N-oxide (TMAO). In contrast, atorvastatin affects hyperlipidemia mainly during lipid metabolism and protein metabolism in vivo.

Show MeSH
Related in: MedlinePlus